ArticlePharmaceuticals (Basel, Switzerland)2017
Precipitation and Neutralization of Heparin from Different Sources by Protamine Sulfate.
Article in Pharmaceuticals (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Engineering Host-Guest Interactions for Next-Generation Heparin Biosensors.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Synergistic effects of multi-frequency ultrasound on the physicochemical properties, molecular structure, and functional indicators ofFood chemistry: X · 2026Article
- Heparin: Over 100 Years of Anticoagulation.Handbook of experimental pharmacology · 2026Review
- Green biosynthetic silver nanoparticles fromMaterials today. Bio · 2025Article
- Unfractionated heparin may improve near-term survival in patients admitted to the ICU with sepsis attributed to pneumonia: an observational study using the MIMIC-IV database.Frontiers in pharmacology · 2025Article
- Minimum protamine dose required to neutralize heparin in cardiac surgery: a single-centre, prospective, observational cohort study.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2023Observational
- Hydrophobicity of arginine leads to reentrant liquid-liquid phase separation behaviors of arginine-rich proteins.Nature communications · 2022Article
- Dilemmas in the Choice of Adequate Therapeutic Treatment in Patients with Acute Pulmonary Embolism-From Modern Recommendations to Clinical Application.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Review
- Building Block Analysis of ATIII Affinity Fractions of Heparins: Application to the ATIII Binding Capacity of Non-conventional 3-Frontiers in medicine · 2022Article
- Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.British journal of pharmacology · 2021Article
- Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood.PloS one · 2020Article
- Revisiting the Pharmacology of Unfractionated Heparin.Clinical pharmacokinetics · 2019Review
- Heparins Sourced From Bovine and Porcine Mucosa Gain Exclusive Monographs in the Brazilian Pharmacopeia.Frontiers in medicine · 2019Review
- Glycosaminoglycans and Proteoglycans.Pharmaceuticals (Basel, Switzerland) · 2018Article
- Article
- Bovine Mucosal Heparins Are Comparable to Porcine Mucosal Heparin at USP Potency Adjusted Levels.Frontiers in medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current therapeutic unfractionated heparin available in Europe and US is of porcine mucosal origin. There is now interest, specifically in the US, to use bovine mucosa as an additional source for the production of heparin. The anticoagulant action of heparin can be neutralized by protamine sulfate, and in this study the ability of protamine to bind and neutralize the anticoagulant activities of heparin from porcine mucosa, bovine mucosa and bovine lung were assessed. Protamine sulfate was able to bind and precipitate similar amounts of heparins from different sources on a mass basis. However, differential amounts of anticoagulant activities were neutralized by protamine sulfate, with neutralization of porcine mucosa more effective than for bovine lung and bovine mucosa. For all heparins, potentiation of thrombin inhibition by antithrombin and heparin cofactor II was preferentially neutralized over antithrombin-mediated inhibition of factor Xa or plasma clotting time. Whole blood thromboelastography showed that neutralization by protamine sulfate was more effective than the antithrombin dependent thrombin inhibition assays indicated. While there was no absolute correlation between average or peak molecular weight of heparin samples and neutralization of anticoagulant activity, correlation was observed between proportions of material with high affinity to antithrombin, specific activities and neutralization of activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.